Next, we investigated the role of canonical WNT/β-catenin signaling in maintaining TICs in murine ICC by treating Krt19-DreER, Axin2-CreER, R26-Ai66, and WT mice with XAV-939, a potent tankyrase inhibitor targeting WNT/β-catenin signaling (Figure 3O). Here, AXIN2 is linked to intrahepatic cholangiocarcinoma.